Obesity is an indication for drug development with over 520 pipeline drugs currently active. According to GlobalData, preregistered drugs for Obesity have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Obesity compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Obesity overview
Obesity, a complex medical condition characterized by excessive body fat accumulation, significantly impacts health and well-being. It increases the risk of developing various chronic diseases like type 2 diabetes, cardiovascular diseases, and certain cancers. Factors such as genetics, diet, physical activity levels, and environmental influences contribute to obesity. Prevention and management strategies include lifestyle modifications such as adopting a balanced diet, increasing physical activity, and seeking professional support. Addressing obesity not only improves individual health outcomes but also reduces the burden on healthcare systems and promotes a healthier society overall.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Obesity, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
